

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 818 439 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
13.10.1999 Bulletin 1999/41

(21) Application number: 97110628.1

(22) Date of filing: 28.06.1997

(51) Int Cl.⁶: **C07C 233/31**, C07D 207/26,
C07D 263/22, C07D 223/10,
C07D 233/38, C07D 213/56,
C07D 307/54, C07D 317/60,
C07D 333/60, A61K 31/16,
A61K 31/40, A61K 31/42,
A61K 31/415, A61K 31/435,
A61K 31/55

(54) **Imide derivatives**

Imid derivate

Dérivés d'imides

(84) Designated Contracting States:
CH DE FR GB IT LI NL

(30) Priority: 02.07.1996 JP 17214896

(43) Date of publication of application:
14.01.1998 Bulletin 1998/03

(73) Proprietor: **NISSHIN FLOUR MILLING CO., LTD.**
Chuo-ku, Tokyo 103 (JP)

(72) Inventors:
• Yokoyama, Shinji, Nisshin Flour Mill. Co., Ltd.
Ohimachi, Iruma-gun, Saitama-ken (JP)
• Sueda, Noriyoshi, Nisshin Flour Mill. Co., Ltd.
Ohimachi, Iruma-gun, Saitama-ken (JP)

- Yamada, Hiroaki, Nisshin Flour Mill. Co., Ltd.
Ohimachi, Iruma-gun, Saitama-ken (JP)
- Kojima, Ryotaro, Nisshin Flour Mill. Co., Ltd.
Ohimachi, Iruma-gun, Saitama-ken (JP)
- Katsuyama, Koichi
Koami-cho, Chuo-ku, Tokyo (JP)

(74) Representative: Türk, Gille, Hrabal
Patentanwälte - European Patent Attorneys,
Brucknerstrasse 20
40593 Düsseldorf (DE)

(56) References cited:
EP-A- 0 720 849 WO-A-92/14455
WO-A-95/01348 WO-A-96/20705
WO-A-96/20926

EP 0 818 439 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

FIELD OF THE INVENTION

5 [0001] This invention relates to novel imide derivatives and pharmaceutical compositions comprising as an active ingredient said imide derivatives or pharmaceutically acceptable salts thereof. More particularly, this invention is concerned with a new class of imide derivatives having a propioloyl group and pharmaceutically acceptable salts thereof as well as pharmaceutical compositions for inhibiting the production of Interleukin-1 β (hereinafter referred to as IL-1 β) and Tumor Necrosis Factor α (hereinafter referred to as TNF α) which comprises as an active ingredient at least one of the imide derivatives or pharmaceutically acceptable salts thereof, which are useful as a therapeutic agent for particularly chronic rheumatism, sepsis, ulcerative colitis or Crohn's disease.

BACKGROUND OF THE INVENTION


15 [0002] IL-1 β and TNF α are a protein produced mainly from immunocompetent cells such as macrophages and neutrophils and an important factor for immune response. Also, they are known to be a factor playing a central role in the inflammatory process or a factor participating in many vital reactions in the hematopoiesis, internal secretion and nervous systems.

20 [0003] There has been recently clarified the relationship between IL-1 β and inflammatory diseases such as chronic rheumatism. For instance, IL-1 β and TNF α were detected in the synovial membrane of patients suffering from chronic rheumatism. It is also reported that the IL-1 β and TNF α levels in the synovial fluid correlate with observations on the local inflammation.

25 [0004] Presently, steroidal agents and non-steroidal antiinflammatory agents have been used for the treatment of inflammatory diseases such as chronic rheumatism. Steroidal agents can achieve remarkable improvement in various symptoms of inflammatory diseases, but they present the problems that drug tolerance may be developed by administration over a prolonged period of time and that side-effects, sometimes serious, such as gastrointestinal disturbance, dermatopathy, and nephritis may be caused. Non-steroidal antiinflammatory agents can temporarily inhibit inflammatory symptoms, but they can not radically cure inflammatory diseases.


30 DETAILED DESCRIPTION OF THE INVENTION

[0005] The present invention provides an imide compound of formula (I)



40 wherein,

R₁ is hydrogen, halogen, trifluoromethyl or cyano;
R₂ is hydrogen, C₁-C₄ alkyl, di(C₁-C₄)alkylamino(C₁-C₄)alkyl, a group of formula (i)




50 wherein n is an integer of 0-3, R₄ and R₅ each independently represent hydrogen, halogen, C₁-C₄ alkyl or C₁-C₄ alkoxy, or R₄ and R₅ jointly may be methylenedioxy or a group of formula (ii)




wherein n is an integer of 0-3 and Het represents a 5- or 6-membered heterocyclic group having nitrogen or oxygen

as a hetero atom;

R₃ is C₁-C₄ alkyl, C₁-C₄ alkoxy(C₁-C₄)alkyl, a group of formula (iii)




wherein n is an integer of 0-3, and R₆ is hydrogen or halogen or a 5- or 6-membered heterocyclic group having nitrogen, oxygen or sulfur as a hetero atom; or R₂ and R₃, together with a nitrogen atom to which R₂ is attached and a carbonyl group to which R₃ is attached, may form a heterocyclic group of formula (iv)




wherein m is an integer of 1-4, Z is -CH₂-, -NH- or -O-, R₇ is hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy carbonyl or phenylpropionyl or a pharmaceutically acceptable salt thereof.

[0006] The present invention also provides a process for the preparation of an imide compound of formula (I) which comprises reacting a carboxylic acid halide of formula (II)




wherein R₁ is as defined above and Hal is halogen, with an amide compound of formula (III)




wherein R₂ and R₃ are as defined above and Y is an alkali metal atom or a trialkylsilyl group, to form an imide compound of formula (I) and if necessary, converting the imide compound of formula (I) to the corresponding pharmaceutically acceptable salt thereof.

[0007] The invention further provides a process for the preparation of an imide compound of formula (I) which comprises reacting a carboxylic acid halide of formula (II)



wherein R₁ is as defined above and Hal is halogen, with an amide compound of formula (IV)



wherein R_2 and R_3 are as defined above, in the presence of a base to form an imide compound of formula (I) and if necessary, converting the imide compound of formula (I) to the corresponding pharmaceutically acceptable salt thereof.

[0008] The invention still further provides a pharmaceutical composition which comprises as an active ingredient at least one of the imide compounds of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. More particularly, the invention is concerned with a pharmaceutical composition for inhibiting the production of IL-1 β and TNF α which comprises as an active ingredient at least one of the imide compounds of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0009] The term "halogen" as used herein includes fluorine, chlorine, bromine or iodine.

[0010] The term "C₁-C₄ alkyl" as used herein refers to a straight or branched alkyl group of 1-4 carbon atoms, which includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.

[0011] The term "C₁-C₄ alkoxy" as used herein refers to a straight or branched alkoxy of 1-4 carbon atoms, which includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy.

[0012] The term "di(C₁-C₄)alkylamino(C₁-C₄)alkyl" as used herein refers to a dialkylaminoalkyl group wherein each alkyl moiety has 1-4 carbon atoms, which includes, for example, dimethylaminomethyl, dimethylaminoethyl, dimethylaminoisopropyl, diethylaminomethyl, diethylaminoethyl, diethylaminoisopropyl, diethylamino-n-propyl, dimethylamino-n-butyl, diisopropylaminomethyl, diisopropylaminoethyl, diisopropylaminoisopropyl and diisopropylamino-n-butyl.

[0013] The term "C₁-C₄ alkoxy(C₁-C₄)alkyl" as used herein refers to an alkoxyalkyl group wherein said alkoxy moiety has 1-4 carbon atoms and said alkyl moiety has 1-4 carbon atoms, which includes, for example, methoxymethyl, methoxyethyl, methoxy-n-propyl, methoxy-n-butyl, ethoxymethyl, ethoxyethyl, ethoxy-n-propyl, ethoxy-n-butyl, n-propoxymethyl, n-propoxyethyl, n-propoxy-isopropyl, n-propoxy-n-butyl, n-butoxymethyl, n-butoxyethyl, n-butoxy-n-propyl and n-butoxy-n-butyl.

[0014] The term "C₁-C₄ alkoxy-carbonyl" as used herein refers to an alkoxy-carbonyl group wherein said alkoxy moiety has 1-4 carbon atoms, which includes, for example, methoxy-carbonyl, ethoxy-carbonyl, n-propoxy-carbonyl, isopropoxy-carbonyl, n-butoxy-carbonyl and tert-butoxy-carbonyl.

[0015] The term "5- or 6-membered heterocyclic group having nitrogen or oxygen as a hetero atom" and the term "5- or 6-membered heterocyclic group having nitrogen, oxygen or sulfur as a hetero atom" refers to any of those 5- or 6-membered heterocyclic groups having at least one of the hetero atoms of N, O and S well-known in the art, which includes, for example, furyl, thienyl, pyrrolyl, oxazolyl, isooxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyridyl, pyrazinyl, pyridazinyl, piperidinyl, piperazinyl, pyranyl, thiopyranyl and morpholinyl.

[0016] In formula (I) or (iii), the substituent R_1 or R_6 may be attached to the phenyl moiety at any of o-, m- and p-positions to the propioloyl moiety or the alkylene moiety.

[0017] In formula (i) or (ii), the $-(CH)_n-$ moiety when n is 1-3 may be a straight or branched alkylene of 1-3 carbon atoms, e.g., methylene, ethylene or propylene.

[0018] Specific examples of the imide compounds of this invention will be illustrated, without any limitation, as shown in the following Table 1 and Table 2.

Table 1




























Compound No.	R_1	
1	H	
2	p-Cl	"
3	p-F	"
4	p-CN	"
5	p-CN	
6	p-F	"
7	H	"
8	H	
9	H	
10	H	
11	H	
21	H	

Table 2

<u>Compound No.</u>	<u>R₁</u>	<u>R₂</u>	<u>R₃</u>
12	H	Et	
13	H		
14	H	H	Me
15	H		Me
16	H	n Bu	n Bu
17	H		Me
18	H	Et	Me
19	H	Et	
20	H		
22	H		Me
23	H		Me

5	24	H		Me
10	25	H	Et	
15	26	H		Me
20	27	H		
25	28	H		Me
30	29	H	Et	
	30	H		Me

[0019] The imide compounds of formula (I) of this invention can be prepared by reacting the carboxylic acid halide of formula (II) with the amide compound of formula (III), or by reacting the carboxylic acid halide of formula (II) with the amide compound of formula (IV) in the presence of a base. Both reactions may be carried out in a conventional manner known to a person skilled in the art.

[0020] The base which may be used in the reaction of the halide (II) and the amide compound (IV) may be any bases usually used for this reaction in the art, such as an alkaline or alkaline earth metal hydroxide, e.g., potassium or sodium hydroxide; an alkaline metal alkoxide, e.g., sodium methoxide; an alkaline or alkaline earth metal carbonate, e.g., potassium or sodium carbonate; an organic amine, e.g., pyridine or dimethylaniline; and the like.

[0021] The reaction parameters (such as reaction temperature, reaction time and others) for the two reactions may be any of those commonly used for these types of the reactions in the art.

[0022] One of the reactants, the carboxylic acid halide of the formula (II), may be easily prepared by reacting phenylpropionic acid with a halogenating agent. This halogenation reaction may be carried out by reacting phenylpropionic acid with the halogenating reagent preferably under the atmosphere of an inert gas such as argon, nitrogen and the like in the presence or absence of a solvent such as anhydrous benzene or anhydrous toluene under reflux.

[0023] The carboxylic acid halides which may be used herein may be, for example, a carboxylic acid fluoride, a carboxylic acid chloride, a carboxylic acid bromide, a carboxylic acid iodide. Typically used is a carboxylic acid chloride in view of easy availability of halogenating agents, its higher reactivity and other factors. For the synthesis of carboxylic acid chlorides, there may be desirably used such halogenating agents as oxalyl chloride, phosphorus pentachloride, phosphorus trichloride, thionyl chloride and the like. Halogenating agents for the synthesis of other carboxylic acid halides may be chosen correspondingly to those of the carboxylic acid chloride.

[0024] In the amide derivative of the formula (III), when Y is an alkali metal, it may be sodium, lithium, potassium and others and, when Y is a trialkylsilyl group, it may be those trialkylsilyl groups wherein said alkyl moiety is as defined above such as a trimethylsilyl, triethylsilyl or tripropylsilyl group. When the amide derivative of the formula (III) wherein Y is a trimethylsilyl group is used, silylation may be easily carried out, for example, by reacting the free amide derivative with 1-10 equivalents of hexamethylenedisilazane in the presence or absence of a solvent such as toluene and the like, preferably under reflux. The reaction of the carboxylic acid chloride with the trimethylsilylated amide derivative

may be preferably carried out in the presence of a solvent at a temperature from 0°C to a reflux temperature of the solvent used.

[0025] Examples of the solvents which may be used in the present reactions include an aromatic hydrocarbon such as benzene, toluene or xylene; an aliphatic hydrocarbon such as n-hexane or petroleum ether; an alicyclic hydrocarbon such as cyclohexane; a halogenated hydrocarbon such as carbon tetrachloride, chloroform, dichloroethane or trichloroethane; a cyclic ether such as tetrahydrofuran or dioxane; an ester such as ethyl acetate or butyl acetate; a ketone such as acetone or methyl ethyl ketone; dimethylformamide; dimethyl sulfoxide; and the like.

[0026] After completion of the reaction, the desired imide compound of formula (I) may be recovered and purified according to a conventional method.

[0027] The imide compounds of formula (I) according to this invention may be converted to the corresponding pharmaceutically acceptable acid addition salts, if desired. It is also contemplated that a pharmaceutical composition comprising the acid addition salts of the present imide compounds is included in the scope of this invention. Examples of the acid addition salts include those with inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid or phosphoric acid; organic sulfonic acids such as methanesulfonic acid, benzenesulfonic acid or p-toluenesulfonic acid; organic carboxylic acids such as acetic acid, propionic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid or citric acid.

[0028] The pharmaceutically acceptable acid addition salts of the imide compounds of formula (I) may be prepared according to a conventional method for forming an acid addition salt.

[0029] The imide compounds or pharmaceutically acceptable salts thereof according to this invention have a potent inhibitory activity on the production of IL-1 β and also a potent inhibitory activity on the production of TNF α with a lower toxicity, thus being useful for the prophylaxis and treatment of those diseases in which IL-1 β and/or TNF α would participate, for example, chronic rheumatism, osteoarthritis, sepsis, ulcerative colitis, Crohn's disease, Behcet's disease, systemic lupus erythematosus, scleroderma, multiple sclerosis, Kawasaki disease, Guillain-Barre syndrome, rejection in organ transplantation, nephritis, hepatitis, pancreatitis, periarteritis nodosa, cephalomeningitis, meningitis, periodontitis, burn, keloid, hypertrophic scar, corneal ulceration, psoriasis, urticaria, atopic dermatitis, pollen allergy, asthma, bronchitis, hyperventilation in adults, malaria, hemicrania, anorexia, Creutzfeldt-Jakob disease, osteoporosis, type II diabetes mellitus (NIDDM), gout, atherosclerosis, dialysis hypotension, cachexia by cancer or infectious disease, acquired immune deficiency syndrome (AIDS) and the like.

[0030] In particular, they are effective for the prophylaxis and treatment of chronic rheumatism, sepsis, colitis ulcerosa and Crohn's disease.

[0031] The effective dose of the present imide compound or pharmaceutically acceptable salt thereof to exert its activity may be usually in the range of from 5 mg to 6 g, preferably 10 mg to 300 mg, daily for an adult. The active compound may be administered, for example, orally, intravenously, subcutaneously, intramuscularly, rectally or intraarticularly and preferably via oral, intraarticular or intravenous route.

[0032] The active compound may be formulated into a pharmaceutical preparation by a conventional method usually employed in the art.

[0033] The pharmaceutical preparation for oral administration includes tablets, granules, powders, hard capsules, soft capsules, oral solutions and the like.

[0034] The tablets or capsules to be orally administered may contain any conventional additives such as binders, e.g., crystalline cellulose, mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, Macrogol (polyethylene glycol) and the like; excipients, e.g., lactose, corn starch, calcium phosphate, magnesium aluminum metasilicate and the like; lubricants, e.g., calcium stearate, talc and the like; disintegrators, e.g., carboxymethylcellulose and the like; and other additives. These preparations may be coated by a conventional coating method well-known in the art.

[0035] The liquid preparations to be orally administered may be aqueous or oily suspensions, emulsions, solutions, syrups, elixirs or other dosage forms, or they may be a dried product to be redissolved in water or other suitable vehicle before use. These liquid preparations may contain any additives commonly used in the art such as suspending agents, e.g., sorbitol syrup, carboxymethylcellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, aluminum stearate gel, hardened oils and the like; emulsifying agents, e.g., lecithin, monooleic acid esters, sorbitan esters, acacia and the like; non-aqueous vehicles, e.g., palm oil, oily esters, propylene glycol, ethyl alcohol and the like; antiseptics, e.g., p-hydroxybenzoic acid esters, sorbic acid and the like; and others.

[0036] The preparation to be parenterally administered may be injections, suppositories and others. The injections may be prepared in a conventional manner by further adding, if desired, pH adjusters, buffers, stabilizers, preservatives, solubilizing agents and others.

[0037] This invention will be further illustrated by the following examples.

Example 1

Preparation of Starting Materials

5 1) Synthesis of substituted phenylpropionic acid

[0038]

i) Synthesis of 4-halophenylpropionic acid

10 A mixture of 4-fluorobenzaldehyde (6.21 g), ethyl diethylphosphonoacetate (11.2 g), potassium carbonate (3.6 g) and methanol (60 ml) was refluxed for 2 hours. To the reaction mixture was added water, extracted with ethyl acetate and the solvent was distilled off to give 8.87 g of crude 4-fluorocinnamic acid ester (a mixture of the methyl ester and the ethyl ester). This crude product was dissolved in 60 ml of methylene chloride. The resulting solution was cooled to 0°C and 2.7 ml of bromine was added dropwise and the mixture was allowed to react for one hour.

15 Then, 2 ml of isoprene was added and the solvent was distilled off to give 16.3 g of an oily substance. This substance was dissolved in 60 ml of toluene, 11.0 g of potassium hydroxide was added portionwise under reflux and then refluxing was continued for further one hour. The reaction mixture was allowed to cool, water was added followed by stirring, the aqueous layer was separated and made acidic with diluted hydrochloric acid, the crystalline substance thus formed was filtered and crystallized successively with chloroform and then hot water to give 1.7 g of

20 4-fluorophenylpropionic acid.

By repeating the same reaction procedures as described above using as the starting material 4-chlorobenzaldehyde was prepared 4-chlorophenylpropionic acid.

ii) Synthesis of 4-cyanophenylpropionic acid

25 Carbon tetrabromide (5.47 g) was dissolved in 50 ml of methylene chloride, cooled to 0°C, triphenylphosphine (8.66 g) was added, to the resulting orange solution was added 4-cyanobenzaldehyde (1.97 g) and the mixture was allowed to react at room temperature for one hour. The reaction mixture was concentrated and purified by a silica gel column chromatography to give 3.82 g of a crystalline substance. This substance was dissolved in 50 ml of anhydrous THF, 2 equivalents of n-butyl lithium was added at -78°C, allowed to rise to room temperature and the reaction was carried out for one hour. After cooling again to -78°C, the reaction mixture was further allowed


30 to rise to room temperature. The reaction mixture was concentrated, the residue was dissolved in 5% aqueous sodium hydroxide, extracted with isopropyl ether, the aqueous layer was separated and made acidic with the addition of conc. hydrochloric acid, the crystalline substance and oily substance thus separated out were extracted with ethyl acetate and crystallized from ether to give 1.0 g of 4-cyanophenylpropionic acid.

iii) Synthesis of phenylpropionic chloride

35 Phenylpropionic chloride was prepared by refluxing phenylpropionic acid and an excess of thionyl chloride according to a conventional method, distilling off the thionyl chloride and then purifying with distillation.

Example 2

40 [0039]



1) Synthesis (I)

50 [0040] A mixture of 2-pyrrolidone (2.13 g, 25 mmole) and hexamethyldisilazane (12.1 g, 75 mmole) was refluxed for 9 hours and an excess of hexamethyldisilazane was distilled off under reduced pressure to afford N-trimethylsilylated 2-pyrrolidone (hereinafter referred to as "TMS product of 2-pyrrolidone"). The resulting TMS product of 2-pyrrolidone was dissolved in 12 ml of toluene, phenylpropionyl chloride (12.5 mmole) was added and refluxed. The reaction mixture

55 was concentrated, the residue was dissolved in ethyl acetate, aqueous sodium hydrogencarbonate was added and the mixture was stirred for 0.5 hour. The ethyl acetate layer was separated, washed with saturated aqueous sodium chloride, dried and then the solvent was distilled off under reduced pressure, purified by silica gel column chromatography and crystallized from ether to give 1.25 g of Compound 1.

Yellow crystals, m.p. 97°C

¹H NMR (CDCl₃ δ) 7.65(2H, d, J=7.8Hz), 7.45(1H, t, J=6.8Hz), 7.36(2H, t, J=7.3Hz), 3.89(2H, t, J=7.3Hz), 2.65(2H, t, J=7.8Hz), 2.10(2H, quintet, J=7.8Hz)


5 2) Synthesis (II)

[0041] A solution of 2-pyrrolidone (2.13 g, 25 mmole) in 100 ml of anhydrous THF was cooled to -78°C. One equivalent of a hexane solution of n-butyl lithium was added dropwise, the mixture was allowed to rise to room temperature and the reaction was carried out for one hour. After cooling again to -78°C, phenylpropioloyl chloride (25 mmole) was added and the mixture was allowed to rise to room temperature and the reaction was carried out for one hour. Aqueous sodium hydrogencarbonate was added, the resulting mixture was stirred for 0.5 hour, 100 ml of ethyl acetate was added, the organic layer was separated and washed with saturated aqueous solution of sodium chloride, dried and then the solvent was distilled off under reduced pressure, purified by silica gel column chromatography, crystallized from ether to afford Compound 1.

15 Example 3

[0042]

20



25

[0043] Compound 2 was prepared by refluxing 4-chlorophenylpropioloyl chloride and TMS product of 2-pyrrolidone in toluene and crystallizing from ether (Yield = 57%).


Yellow crystals, m.p. 158°C

¹H NMR (CDCl₃ δ) 7.60(2H, d, J=8.8Hz), 7.36(2H, d, J=8.3Hz), 3.89(2H, t, J=7.3Hz), 2.66(2H, t, J=7.7Hz), 2.11(2H, quintet, J=7.3Hz)

Example 4

[0044]

40



[0045] Compound 3 was prepared by refluxing 4-fluorophenylpropioloyl chloride and TMS product of 2-pyrrolidone in toluene, purifying by silica gel column chromatography and then crystallizing from methanol (Yield = 48%).

Colorless crystals, m.p. 158°C


¹H NMR (CDCl₃ δ) 7.67(2H, dd, J=9.3, 6.1Hz), 7.80(2H, t, J=8.8Hz), 3.89(2H, t, J=7.3Hz), 2.66(2H, t, J=7.8Hz), 2.11(2H, q, J=7.4Hz)

50

55

Example 5

[0046]




10 [0047] The Compound 4 was prepared by refluxing 4-cyanophenylpropiolyl chloride and TMS product of 2-pyrrolidone in toluene, purifying by silica gel column chromatography and crystallizing from methanol (Yield = 14%).

Colorless crystals, m.p. 103°C

15 ¹H NMR (CDCl₃ δ) 7.74(2H, d, J=8.8Hz), 7.68(2H, d, J=8.8Hz), 3.90(2H, t, J=7.4Hz), 2.67(2H, t, J=8.3Hz), 2.13(2H, q, J=7.6Hz)

Example 6

[0048]




25 [0049] Compound 5 was prepared by refluxing 4-cyanophenylpropiolyl chloride and TMS product of 2-oxazolidone in toluene, purifying by silica gel column chromatography and crystallizing from methanol (Yield = 56%).

Colorless crystals, m.p. 169°C

30 ¹H NMR (CDCl₃ δ) 7.76(2H, d, J=8.3Hz), 7.68(2H, d, J=8.3Hz), 4.49(2H, t, J=7.8Hz), 4.11(2H, t, J=7.8Hz)

Example 7

[0050]




40 [0051] Compound 6 was prepared by refluxing 4-fluorophenylpropiolyl chloride and TMS product of 2-oxazolidone in toluene, purifying by silica gel column chromatography and crystallizing from methanol.

Colorless crystals, m.p. 149°C

45 ¹H NMR (CDCl₃ δ) 7.69(2H, dd, J=8.3, 5.3Hz), 7.09(2H, t, J=8.8Hz), 4.47(2H, t, J=7.8Hz), 4.11(2H, t, J=7.8Hz)

Example 8

[0052]




[0053] Compound 7 was prepared by refluxing phenylpropioloyl chloride and TMS product of 2-oxazolidone in toluene, purifying by silica gel column chromatography and crystallizing from methanol (Yield=56%). Colorless crystals, m.p. 169°C

¹H NMR (CDCl₃ δ) 7.68(2H, td, J=6.8, 1.5Hz), 7.47(1H, tt, J=6.8, 1.5Hz), 7.39(2H, tt, J=6.8, 1.5Hz), 4.47(2H, t, J=8.3Hz), 4.11(2H, t, J=8.3Hz)

Example 9

[0054]




[0055] Compound 8 was prepared by refluxing phenylpropioloyl chloride and TMS product of ε-caprolactam in toluene and purifying by silica gel column chromatography (Yield=82%).

Yellow oily substance
¹H NMR (CDCl₃ δ) 7.64(2H, dt, J=8.3, 2.0Hz), 7.43(1H, tt, J=7.3, 2.4Hz), 7.36(2H, tt, J=6.8, 1.4Hz), 3.97(2H, t, J=5.1Hz), 2.77(2H, t, J=4.6Hz), 1.74-1.84(6H, m)

Example 10

[0056]





[0057] Compound 9 was prepared by refluxing phenylpropioloyl chloride and TMS product of 5-methyl-2-pyrrolidone in toluene, purifying by silica gel column chromatography and crystallizing from hexane (Yield=45%).

Yellow crystals, m.p. 79°C
¹H NMR (CDCl₃ δ) 7.67(2H, dt, J=6.8, 1.5Hz), 7.45(1H, tt, J=7.3, 1.5Hz), 7.38(2H, tt, J=7.3, 1.5Hz), 4.54(1H, qd, J=7.3, 2.0Hz), 2.76(1H, quintet-d, J=8.8, 2.4Hz), 2.56(1H, qd, J=8.8, 2.4Hz), 2.24(1H, quintet-d, J=10.7, 3.4Hz), 1.76(1H, tt, J=11.7, 2.0Hz), 1.38(3H, d, J=6.8Hz)

Example 11

[0058]



[0059] Compound 10 and Compound 11 with a high polarity were separated by refluxing phenylpropioloyl chloride and TMS product of propylene urea in toluene and purifying by silica gel column chromatography.

Data for Compound 10

Orange crystals, m.p. 204°C

¹H NMR (CDCl₃ δ) 7.72(4H, dd, J=7.8, 2.0Hz), 7.49(2H, tt, J=7.3, 2.0Hz), 7.41(4H, t, J=7.8Hz), 3.99(4H, s)


Data for Compound 11

Pale yellow crystals, m.p. 164°C

¹H NMR (CDCl₃ δ) 7.66(2H, dd, J=6.3, 2.0Hz), 7.44(1H, tt, J=7.8, 2.0Hz), 7.37(2H, t, J=7.8Hz), 5.02(1H, brs), 4.05(2H, t, J=7.8Hz), 3.56(2H, t, J=7.8Hz)

Example 12

[0060]



[0061] A mixture of TMS product of N-ethylbenzamide (1.81 g) and phenylpropioloyl chloride (1.0 g) in toluene was refluxed for 3.5 hours and worked up according to a conventional method and purified by silica gel column chromatography to give 0.47 g of Compound 12 as an oily substance (Yield=28%), which was then allowed to stand to crystallize.

Data for Compound 12

m.p. 64-69°C


¹H NMR (CDCl₃ δ) 7.72(2H, m), 7.2-7.55(6H, m), 7.10(2H, m), 4.07(2H, q), 1.35(2H, t)

IR(KBr cm⁻¹) 2212 1692 1659 1651 1351 1267 1110

MS 277(M⁺)

Example 13

[0062]



[0063] A mixture of TMS product of N-(4-fluorobenzyl)-benzamide (1.57 g) and phenylpropioloyl chloride (1.0 g) in toluene was refluxed for 2 hours and worked up according to a conventional method and purified by silica gel column chromatography to give 0.60 g of Compound 13 as an oily substance (Yield=28%).

Data for Compound 13


¹H NMR (CDCl₃ δ) 7.66(2H, m), 7.4-7.54(5H), 7.34(1H, m), 7.24(2H, m), 7.03(4H, m), 5.16(2H, s)

IR(neat cm⁻¹) 2210 1694 1644 1510 1339 1094 965

MS 357(M⁺)

Example 14

[0064]



[0065] A mixture of N-trimethylsilylacetamide (1.0 g) and phenylpropioloyl chloride (1.0 g) in toluene was refluxed for 6 hours, worked up according to a conventional method, purified by silica gel column chromatography and recrystallized from chloroform-hexane to give 0.16 g of Compound 14 (Yield=14%).

Data for Compound 14


m.p. 103-107.5°C

¹H NMR (CDCl₃ δ) 8.36(1H, bs), 7.59(2H, m), 7.49(1H, m), 7.41(2H, m), 2.49(3H, m)

IR (KBr cm⁻¹) 2210 1715 1692 1667 1498 1376 1161 1028

Example 15

[0066]



[0067] A mixture of TMS product of N-(3,4-methylenedioxyphenyl)acetamide (1.81 g) (which was synthesized by refluxing the acetamide, HMDS and a small amount of DMF for 20 hours) and phenylpropioloyl chloride (1.0 g) in toluene was refluxed for 3 hours, worked up according to a conventional method, purified by silica gel column chromatography and recrystallized from chloroform-hexane to give 0.89 g of Compound 15 (Yield=48%).


Data for Compound 15

m.p. 129-130°C

¹H NMR (CDCl₃ δ) 7.2-7.43(5H), 6.90(1H, d), 6.76(2H, m), 6.05(2H, s), 2.62(3H, s)

Example 16

[0068]



[0069] A mixture of TMS product of N-(n-butyl)-n-pentaneamide (1.5 g) and phenylpropioloyl chloride (0.9 g) in toluene was refluxed for 2 hours, worked up according to a conventional method, purified by silica gel column chromatography to give 0.39 g of Compound 16 as an oily substance (Yield=25%).


Data for Compound 16

¹H NMR (CDCl₃ δ) 7.57(2H, m), 7.49(1H, m), 7.41(2H, m), 4.00(2H, t), 2.93(2H, t), 1.67(4H, m), 1.39(4H, m), 0.97(3H, t), 0.93(3H, t)

IR (neat cm⁻¹) 2210 1704 1671 1358 1186 1117

Example 17

[0070]



15 [0071] A mixture of TMS product of N-(2-methoxybenzyl)acetamide (1.4 g)(prepared by refluxing the acetamide and HMDS for 24 hours) and phenylpropioloyl chloride (1.0 g) in toluene was heated (90°C) for one hour, worked up according to a conventional method, purified by silica gel column chromatography and recrystallized from chloroform-hexane to give 0.48 g of Compound 17 (Yield=26%).


Data for Compound 17

m.p. 126-127.5°C

20 ¹H NMR (CDCl₃ δ) 7.2-7.45(6H), 7.08(1H, d), 6.92(1H, t), 6.86(1H, d), 5.24(2H, s), 3.82(3H, s), 2.63(3H, s)

Example 18

[0072]



35 [0073] A mixture of TMS product of N-ethylacetamide (1.25 g) and phenylpropioloyl chloride (0.9 g) in toluene was heated (80°C) for 2 hours, worked up according to a conventional method, purified by silica gel column chromatography and recrystallized from ether-hexane to give 0.31 g of Compound 18 (Yield=26%).

Data for Compound 18


m.p. 42-43.5°C

¹H NMR (CDCl₃ δ) 7.58(2H, m), 7.4-7.5(3H), 4.08(2H, q), 2.58(3H, s), 1.31(3H, t)

IR (KBr cm⁻¹) 2204 1698 1669 1357 1241 1102 765

Example 19

[0074]



55 [0075] A mixture of TMS product of N-ethyl-2-chlorophenylacetamide (0.53 g) and phenylpropioloyl chloride (0.4 g) in toluene was refluxed for 8 hours, worked up according to a conventional method, purified by silica gel column chromatography and recrystallized from ether-hexane to give 0.12 g of Compound 19 (Yield=15%).


Data for Compound 19

m.p. 60-61.5°C

¹H NMR (CDCl₃ δ) 7.60(2H, m), 7.38-7.52(4H), 7.24(3H, m), 4.37(2H, s), 4.13(2H, q), 1.34(3H, t)

Example 20

[0076]



[0077] A mixture of TMS product of N-(2-methylphenyl)-3-phenylpropionamide (2.0 g) and phenylpropionoyl chloride (1.0 g) in toluene was heated (100°C) for 2 hours, worked up according to a conventional method and purified by silica gel column chromatography to give 0.85 g of Compound 20 (Yield=35%).


15 Data for Compound 20

¹H NMR (CDCl₃ δ) 7.06-7.41(14H), 3.32(2H, t), 3.06(2H, dt), 2.13(3H, s)

IR (neat cm⁻¹) 2208 1712 1676 1491 1306 1208 1132

Example 21

[0078]




[0079] A mixture of phenylpropionoyl chloride and N-TMS-DL-pyrroglutamic acid methyl ester in toluene was refluxed and purified by silica gel chromatography to give Compound 21 as a yellow oily substance (Yield=67%). Data for Compound 21

¹H NMR (CDCl₃ δ) 7.68(2H, dd, J=7.2, 1.4Hz), 7.47(1H, tt, J=7.7, 1.5Hz), 7.39(2H, td, J=8.3, 1.4Hz), 4.85(1H, dd, J=9.3, 2.6Hz), 3.80(3H, s), 2.73-2.82(1H, m), 2.63(1H, qd, J=9.3, 3.0Hz), 2.35-2.45(1H, m), 2.12-2.20(1H, m)

Example 22

[0080]




[0081] To a solution of 2-acetaminopyridine in anhydrous THF was added dropwise at -78°C one equivalent of a n-butyl lithium solution in hexane, the resulting mixture was allowed to rise to room temperature and the reaction was carried out for one hour. After cooling again to -78°C, phenylpropionoyl chloride was added, the mixture was allowed to rise to room temperature and reacted for one hour. Aqueous sodium hydrogencarbonate was added, the mixture was stirred for 0.5 hour, extracted with ethyl acetate and the solvent was distilled off under reduced pressure, purified by silica gel column chromatography, crystallized from ethyl acetate-hexane. The crystalline substance was converted to the corresponding hydrochloride by a 4N-hydrochloric acid-ethyl acetate solution and recrystallized from ethanol to give Compound 22 (Yield=6%).

Data for Compound 22

Colorless crystals, m.p. 130°C (dec.)

Example 25

[0086]



10

[0087] To a solution of 2-thienylethylamide(thiophenecarbonylethylamide) in anhydrous THF was added dropwise at -78°C one equivalent of a n-butyl lithium solution in hexane, the resulting mixture was allowed to rise to room temperature and reacted for one hour. After cooling again to -78°C, phenylpropionyl chloride was added, the mixture was

15 allowed to rise to room temperature and reacted for one hour. Aqueous sodium hydrogencarbonate was added, the mixture was stirred for 0.5 hour, extracted with ethyl acetate and the solvent was distilled off under reduced pressure, purified by silica gel chromatography to give Compound 25 as a brown substance (Yield=78%), which was crystallized on standing.


Data for Compound 25

m.p. 42°C

20 ¹H NMR (CDCl₃ δ) 7.80(1H, d, J=4.9Hz), 7.66(1H, d, J=3.4Hz), 7.38(1H, t, J=7.2Hz), 7.28(2H, t, J=8.3Hz), 7.20(2H, d, J=6.8Hz), 7.11(1H, t, J=4.9Hz), 4.01(2H, q, J=7.3Hz), 1.34(3H, t, J=7.3Hz)

Example 26

[0088]



35 [0089] To a solution of 4-(acetaminomethyl)pyridine in anhydrous THF was added dropwise at -78°C one equivalent of a n-butyl lithium solution in hexane, the resulting mixture was allowed to rise to room temperature and reacted for one hour. After cooling again to -78°C, phenylpropionyl chloride was added, the mixture was allowed to rise to room temperature and reacted for one hour. Aqueous sodium hydrogencarbonate was added, the mixture was stirred for

40 0.5 hour, extracted with ethyl acetate and the solvent was distilled off under reduced pressure, purified by silica gel column chromatography, converted to the corresponding hydrochloride in chloroform using a 4N hydrochloric acid-ethyl acetate solution and crystallized from isopropyl alcohol to give Compound 26 (Yield=18%).


Data for Compound 26

Colorless crystals, m.p. 130°C (dec.)

45 ¹H NMR (DMSO) 8.96(1H, d, J=5.9Hz), 7.93(1H, d, J=5.4Hz), 7.53(1H, t, J=7.8Hz), 7.42(2H, t, J=7.8Hz), 7.22(2H, d, J=7.8Hz), 2.57(3H, s)

Example 27

[0090]



15 [0091] N-(2,4-Difluorophenyl)benzamide (1.45 g) was reacted with n-butyl lithium in THF and a solution of phenylpropionyl chloride (1.0 g) in THF was added dropwise. The reaction mixture was worked up according to a conventional method and purified by silica gel column chromatography to give 0.77 g of Compound 27 as an oily substance (Yield=35%).


Data for Compound 27

¹H NMR (CDCl₃ δ) 7.82(2H, m), 7.55(1H, m), 7.2-7.5(8H), 6.99(2H, m)

20 IR (neat cm⁻¹) 2208 1699 1612 1509 1268 1198 1174 1144 964 759

Example 28

[0092]



35 [0093] TMS product of N-phenethylacetamide (1.9 g) was reacted with phenylpropionyl chloride (1.2 g) under heating (100°C) in toluene for 2 hours. The reaction mixture was worked up according to a conventional method and purified by silica gel column chromatography to give 0.60 g of Compound 28 as an oily substance (Yield=34%), which crystallized on standing.


Data for Compound 28 m.p. 58-65°C

¹H NMR (CDCl₃ δ) 7.56(2H, m), 7.50(1H, m), 7.42(2H, m), 7.25(5H), 4.23(2H, m), 2.98(2H, t), 2.59(3H, s)

40 IR (KBr cm⁻¹) 2205 1703 1668 1660 1354 1250 1168 1155 764

Example 29

[0094]



55 [0095] N-Ethylmethoxyacetamide (0.77 g) was reacted with n-butyl lithium in THF according to a conventional method and then reacted with phenylpropionyl chloride (1.0 g). The reaction mixture was worked up according to a conventional method, purified by silica gel column chromatography and recrystallized from ether-hexane to give 0.79 g of Compound 29 (Yield=53%).

Data for Compound 29


m.p. 87-88.0°C

¹H NMR (CDCl₃ δ) 7.59(2H, m), 7.49(1H, m), 7.42(2H, m), 4.57(2H, s), 3.49(3H, s), 3.13(2H, q), 1.34(3H, t)

IR (KBr cm^{-1}) 2212 1718 1663 1374 1209 1198 1107 770

Example 30

5 [0096]



15 [0097] N-(2-(N,N-Dimethylamino)ethyl)acetamide (1.52 g) was reacted with n-butyl lithium in THF according to a conventional method and then reacted with phenylpropioloyl chloride (1.2 g). The reaction mixture was worked up according to a conventional method to give 1.55 g of the residue. This residue showed tailing (CHCl_3 -MeOH) on a silica gel plate and decomposition was clearly confirmed by the 2D development. The residue was purified by silica gel column chromatography to give 0.40 g of the desired free base as an oily substance (Yield=21%), which crystallized

20 on standing.

Data for Compound 30

^1H NMR (CDCl_3 δ) 7.58(2H, m), 7.49(1H, m), 7.41(2H, m), 4.11(2H, t), 2.57(3H, s), 2.55(2H, t), 2.30(6H, s)

IR (KBr cm^{-1}) 2214 2198 1701 1662 1354 1243 1151 1073 975 762

25 [0098] The crystal thus obtained was dissolved in chloroform and converted to the corresponding hydrochloride by the addition of 0.40 ml of a 4N hydrochloric acid-acetic acid solution to give Compound 30. Crystallization of this compound was tried, but unsuccessfully and a syrupy product was obtained.

Test Example 1

30 Determination for the inhibitory activity of the IL-1 β production and the inhibitory activity of the TNF α production

[0099] The THP-1 cells, which is the monocyte-established cell line derived from human peripheral blood (ATCC TIB202), were incubated at 37°C in a 5% CO_2 incubator in RPMI 1640 medium (available from Bio-Whittaker Co., Ltd.) containing 10%(v/v) of fetal bovine serum, 2 mM of glutamine, 50 μM of 2-mercaptoethanol, 60 $\mu\text{g}/\text{ml}$ of penicillin and

35 100 $\mu\text{g}/\text{ml}$ of streptomycin. The THP-1 cells maintained as described above were centrifuged at 1200 rpm at room temperature for 3 minutes to recover the cells in a 50ml conical tube. The cell pellets thus obtained were resuspended in RPMI 1640 medium containing 2%(v/v) of fetal bovine serum and the glutamine, 2-mercaptoethanol and antibiotics as described above so as to provide a final THP-1 cell concentration of 2×10^6 cells/ml.

40 [0100] The cell resuspension having the above concentration was dispensed in 0.5 ml portions to a 24-well plate for cell culture. Then, 2.5 μl each of the solutions of the present imide derivatives dissolved in DMSO was added to each well. The plate was then incubated at 37°C in a 5% CO_2 incubator for one hour. Then, 12-o-tetradecanoylphorbol-13-acetate (hereinafter referred to as PMA) and polyinosic acid were added to each well so as to provide the final concentrations of 2 $\mu\text{g}/\text{ml}$ and 200 $\mu\text{g}/\text{ml}$, respectively. The plate was further incubated at 37°C in a 5% CO_2 incubator for 22 hours and the IL-1 β and TNF α produced in the cultured broth were assayed. The assay for IL-1 β was carried

45 out by means of the enzyme immunoassay kit available from Cayman Chemical Co., Ltd., while the assay of TNF α was done by means of the ELIZA kit available from Genzyme Co., Ltd.

[0101] The inhibitory activity was expressed in terms of IC_{50} values, wherein the produced amount of IL-1 β and the produced amount of TNF α when no imide derivative was added are defined as 100, respectively, and the concentration of each imide derivative of the present invention to inhibit the IL-1 β production and TNF α production is defined as IC_{50} .

50 respectively. The results are shown in Table 3.

Table 3

Test Compound (Compound No.)	IC_{50}	
	IL-1 β (μM)	TNF α (μM)
1	1.4	1.0
2	5.5	1.6

55

Table 3 (continued)

Test Compound (Compound No.)	IC ₅₀	
	IL-1 β (μ M)	TNF α (μ M)
3	3.8	1.3
4	7.0	1.7
5	2.6	2.1
6	2.4	1.7
7	1.1	1.2
8	6.0	2.1
9	2.8	0.9
10	0.7	0.5
11	1.8	0.5
12	9.6	5.4
13	15	15
14	4.4	1.8
15	6.3	1.7
16	13	14
17	3.1	1.8
18	5.7	4.4
19	2.0	1.3
20	1.3	1.9
21	7.0	0.6
22	12	14
24	10	4.4
25	>30	4.8
26	8.8	1.7
27	14	3.0
28	8.8	1.7
29	>30	>30
30	6.3	3.7

Test Example 2

Determination for Cytotoxicity

[0102] The THP-1 cells, which is the monocyte-established cell line derived from human peripheral blood (ATCC TIB202), were incubated at 37°C in a 5% CO₂ incubator in RPMI 1640 medium (available from Bio-Whittaker Co., Ltd.) containing 10%(v/v) of fetal bovine serum, 2 mM of glutamine, 50 μ M of 2-mercaptoethanol, 60 μ g/ml of penicillin and 100 μ g/ml of streptomycin. The THP-1 cells maintained as described above were centrifuged at 1200 rpm at room temperature for 3 minutes to recover the cells in a 50 ml conical tube. The cell pellets thus obtained were suspended in RPMI 1640 medium containing 2%(v/v) of fetal bovine serum, 2 mM of glutamine, 50 μ M of 2-mercaptoethanol, 60 μ g/ml of penicillin and 100 μ g/ml of streptomycin so as to provide the final cell concentration of 1 x 10⁶ cells/ml.

[0103] The cell suspension obtained as above was dispensed in 1 ml portions to a 24-well plate for cell culture. Then, 5 μ l each of the solutions of the present imide derivatives dissolved in DMSO was added to each well. The plate was then incubated at 37°C in a 5% CO₂ incubator for 24 hours. After incubation, 100 μ l of Alamar Blue (available from Biosource Co., Ltd.) was added to each well and then the plate was further incubated at 37°C in a 5% CO₂ incubator for 3 hours. Thereafter, a supernatant was recovered and determined for a difference in absorbances at 570 nm and 600 nm. Cytotoxicity was then evaluated in accordance with the survival rates determined from the differences in absorbances. More specifically, the lethal dose for 50% (LD₅₀) in the THP-1 cells were calculated. The results are shown in Table 4.

Table 4

Test Compound	LD ₅₀ (μM)
Compound 1	70
Compound 3	>100
Compound 6	>100
Compound 7	>200
Compound 8	>200
Compound 9	110

Test Example 3

Determination for the inhibitory activity of the TNF α production

[0104] To the DBA/2 strain mice previously given with LPS 5.6 mg/kg, i.v. were intraperitoneally administered twice before and after 30 minutes from the LPS administration the present imide derivatives selected from Compound 1, Compound 3, Compound 7, Compound 8, Compound 9 and Compound 26. After 2 hours from the LPD administration, the blood TNF α level was determined to investigate the inhibitory activity of the present imide derivatives on the TNF α production. More specifically, the blood TNF α level was determined when the present imide derivative was given at a dose of 10 mg/kg to calculate the inhibitory rate of the TNF α production. The results are shown in Table 5. It was confirmed that all of Compounds 1, 3, 7, 8, 9 and 26 exhibit a significant inhibitory activity.

Table 5

Test Compound	Inhibitory rate (%) of TNF α production
Compound 1	22
Compound 3	37
Compound 7	22
Compound 8	31
Compound 9	29
Compound 26	37

Preparation Example 1 Tablets

[0105] Tablets were prepared using the following formulation per tablet:

Tablet Formulation	
Compound 9	20 mg
Magnesium silicate	20 mg
Lactose	98.5 mg
Hydroxypropylcellulose	7.5 mg
Magnesium stearate	1 mg
Hardened vegetable oil	3 mg
Total	150 mg

[0106] Compound 9, magnesium silicate and lactose were blended and kneaded with an alcoholic solution of hydroxypropylcellulose. The resulting mixture was granulated to an appropriate particle size, dried and sized. Then, magnesium stearate and hardened vegetable oil were blended to form uniform granules and then the granules were formed to tablets by means of a rotary tableting machine, each tablet having a diameter of 7.0 mm, a weight of 150 mg and a hardness of 6 kg.

Preparation Example 2 Granules

[0107] Granules were prepared using the following formulation:

Granule Formulation	
Compound 9	10 mg
Magnesium oxide	40 mg
Calcium hydrogenphosphate	38 mg
Lactose	10 mg
Hydroxypropylcellulose	20 mg

[0108] All components listed in the above Formulation except for the hydroxypropylcellulose were blended and then kneaded with an alcoholic solution of hydroxypropylcellulose. The resulting mixture was granulated by means of an extrusion granulating machine and then dried to form granules, which were then sized and passed through a 12 mesh sieve. The product left on a 48 mesh sieve was applied as granules.

Preparation Example 3 Syrups

[0109] Syrups were prepared using the following formulation:

Syrup Formulation	
Compound 9	1.000 g
Sucrose	30.000 g
70w/v% D-Sorbitol	25.000 g
Ethyl p-hydroxybenzoate	0.030 g
Propyl p-hydroxybenzoate	0.015 g
Flavoring agent	0.200 g
Glycerol	0.150 g
96% Ethanol	0.500 g
Purified water	ad lib.
Total	100 ml

[0110] Sucrose, D-sorbitol, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate, and Compound 9 were dissolved in purified water (warm water). After cooling, a solution of the flavoring agent in glycerol and 96% ethanol was added. To the resulting mixture was added purified water to make it up to 100 ml.

Preparation Example 4 Injections

[0111] Injections were prepared using the following formulation:

Injection Formulation	
Hydrochloride of Compound 26	10.0 mg
Sodium chloride	81.0 mg
Sodium bicarbonate	8.40 mg
Distilled water for injection	ad lib.
Total	10.0 ml

[0112] Sodium bicarbonate, sodium chloride and hydrochloride of Compound 26 were dissolved in distilled water for injection to make up a total volume to 10.0 ml.

Preparation Example 5 Suppositories

[0113] Suppositories were prepared using the following formulation:

Suppository Formulation	
Compound 9	2 g


(continued)

Suppository Formulation	
Macrogol 4000 (Polyethylene glycol 4000)	20 g
Glycerol	78 g
Total	100 g

[0114] Compound 9 was dissolved in glycerol and then Macrogol 4000 was added thereto. The resulting mixture was melted with heating, poured into a suppository mold and then solidified by cooling to form suppositories, each weighing 1.5 g.


Claims

1. An imide compound having the formula (I)



wherein,


R_1 is hydrogen, halogen, trifluoromethyl or cyano;
 R_2 is hydrogen, C_1 - C_4 alkyl, di(C_1 - C_4)alkylamino(C_1 - C_4)alkyl, a group of formula (i)



wherein n is an integer of 0-3, R_4 and R_5 each independently represent hydrogen, halogen, C_1 - C_4 alkyl or C_1 - C_4 alkoxy, or R_4 and R_5 jointly may be a methylenedioxy or a group of formula (ii)




wherein n is an integer of 0-3 and Het represents a 5- or 6-membered heterocyclic group having nitrogen or oxygen as a hetero atom;
 R_3 is C_1 - C_4 alkyl, C_1 - C_4 alkoxy(C_1 - C_4)alkyl, a group of formula (iii)



wherein n is an integer of 0-3, and R_6 is hydrogen or halogen or a 5- or 6-membered heterocyclic group having nitrogen, oxygen or sulfur as a hetero atom; or
 R_2 and R_3 together with a nitrogen atom to which R_2 is attached and a carbonyl group to which R_3 is attached

may form a heterocyclic group of formula (iv)




wherein m is an integer of 1-4, Z is -CH₂-, -NH- or -O-, and R₇ is hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy-carbonyl or phenylpropionyl or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein R_1 is hydrogen, halogen, trifluoromethyl or cyano, and R_2 and R_3 , together with a nitrogen atom to which R_2 is attached and a carbonyl group to which R_3 is attached, form a heterocyclic group of formula (iv) wherein m is 1 or 2, Z is $-CH_2-$ or $-NH-$ and R_7 is hydrogen, C_1-C_4 alkoxycarbonyl or phenylpropionyl.
3. The compound of claim 1 wherein R_1 is hydrogen, R_2 is hydrogen, C_1-C_4 alkyl or di(C_1-C_4)alkylamino(C_1-C_4)alkyl, and R_3 is C_1-C_4 alkyl or (C_1-C_4)alkoxy(C_1-C_4)alkyl.
4. The compound of claim 1 wherein R_1 is hydrogen, R_2 is a group of formula (i) wherein n is 0, 1 or 2, R_4 and R_5 each independently represent hydrogen, halogen, C_1-C_4 alkyl or C_1-C_4 alkoxy and R_3 is a group of formula (iii) wherein n is 0, 1 or 2, R_6 is hydrogen or halogen.
5. The compound of claim 1 wherein R_1 is hydrogen, R_2 is a group of formula (i) wherein R_4 and R_5 jointly represent methylenedioxy, and R_3 is C_1-C_4 alkyl.
6. The compound of claim 1 wherein R_1 is hydrogen, R_2 is a group of formula (ii) wherein n is 0 or 1 and Het represents furyl or pyridyl and R_3 is C_1-C_4 alkyl.
7. The compound of claim 1 wherein R_1 is hydrogen, R_2 is C_1-C_4 alkyl and R_3 is thienyl.
8. A pharmaceutical composition which comprises as an active ingredient an imide compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1-7, and a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 8, wherein it is an agent for inhibiting the production of Interleukin- 1β and the production of Tumor Necrosis Factor α .
10. The pharmaceutical composition of claim 8 or 9 wherein it is a therapeutic agent for chronic rheumatism, sepsis, ulcerative colitis or Crohn's disease.
11. The pharmaceutical composition of claim 8 or 9 wherein it is a therapeutic agent for osteoarthritis, Behcet's disease, systemic lupus erythematosus, scleroderma, multiple sclerosis, Kawasaki disease, Guillain-Barre syndrome, rejection in organ transplantation, nephritis, hepatitis, pancreatitis, periarteritis nodosa, cephalomeningitis, meningitis, periodontitis, burn, keloid, hypertrophic scar, corneal ulceration, psoriasis, urticaria, atopic dermatitis, pollen allergy, asthma, bronchitis, hyperventilation in adults, malaria, hemicrania, anorexia, Creutzfeldt-Jakob disease, osteoporosis, type II diabetes mellitus (NIDDM), gout, atherosclerosis, dialysis hypotension, cachexia by cancer or infectious disease, or acquired immune deficiency syndrome (AIDS).


Patentansprüche

1. Imidverbindung der folgenden Formel (I):



worin


R_1 Wasserstoff, Halogen, Trifluormethyl oder Cyano ist;
 R_2 Wasserstoff, $(\text{C}_1\text{-C}_4)$ -Alkyl, Di $(\text{C}_1\text{-C}_4)$ alkylamino- $(\text{C}_1\text{-C}_4)$ alkyl, eine Gruppe der Formel (i)




worin n eine ganze Zahl von 0-3 ist, R_4 und R_5 jeweils unabhängig Wasserstoff, Halogen, $(\text{C}_1\text{-C}_4)$ Alkyl oder $(\text{C}_1\text{-C}_4)$ -Alkoxy darstellen, oder R_4 und R_5 gemeinsam Methylendioxy oder eine Gruppe der Formel (ii) darstellen



worin n eine ganze Zahl von 0-3 ist, und Het eine 5-oder 6-gliedrige heterocyclische Gruppe mit Stickstoff oder Sauerstoff als Heteroatom darstellt;
 R_3 $(\text{C}_1\text{-C}_4)$ Alkyl, $(\text{C}_1\text{-C}_4)$ Alkoxy $(\text{C}_1\text{-C}_4)$ alkyl, eine Gruppe der Formel (iii)



darstellt, worin n eine ganze Zahl von 0-3 ist und R_6 Wasserstoff oder Halogen oder eine 5- oder 6-gliedrige heterocyclische Gruppe mit Stickstoff, Sauerstoff oder Schwefel als Heteroatom ist; oder R_2 und R_3 zusammen mit dem Stickstoffatom, an das R_2 gebunden ist, und der Carbonylgruppe, an die R_3 gebunden ist, eine heterocyclische Gruppe der Formel (iv)



bilden können, worin m eine Zahl von 1-4 ist $\text{Z} = \text{-CH}_2\text{-}$, -NH- oder -O- ist und R_7 Wasserstoff, $(\text{C}_1\text{-C}_4)$ Alkyl, $(\text{C}_1\text{-C}_4)$ Alkoxy-carbonyl oder Phenylpropionyl ist, oder ein pharmazeutisch verträgliches Salz davon.


2. Verbindung nach Anspruch 1, worin R_1 Wasserstoff, Halogen, Trifluormethyl oder Cyano ist, und R_2 und R_3 zusammen mit dem Stickstoffatom, an das R_2 gebunden ist und der Carbonylgruppe, an die R_3 gebunden ist, eine heterocyclische Gruppe der Formel (iv) bildet, worin m 1 oder 2 ist, $\text{Z} = \text{-CH}_2\text{-}$ oder -NH- ist und R_7 Wasserstoff, $(\text{C}_1\text{-C}_4)$

C₄)Alkoxy-carbonyl oder Phenylpropionyloxy ist.

3. Verbindung nach Anspruch 1, worin R₁ Wasserstoff ist, R₂ Wasserstoff, (C₁-C₄)Alkyl oder Di(C₁-C₄)alkylamino (C₁-C₄)-alkyl ist und R₃ (C₁-C₄)Alkyl oder (C₁-C₄)Alkoxy(C₁-C₄)alkyl ist.
4. Verbindung nach Anspruch 1, worin R₁ Wasserstoff ist, R₂ eine Gruppe der Formel (i), worin n 0, 1 oder 2 ist, R₄ und R₅ jeweils unabhängig Wasserstoff, Halogen, (C₁-C₄)alkyl oder (C₁-C₄)Alkoxy darstellen und R₃ eine Gruppe der Formel (iii) ist, worin n 0, 1 oder 2 ist, R₆ Wasserstoff oder Halogen ist.
5. Verbindung nach Anspruch 1, worin R₁ Wasserstoff, R₂ eine Gruppe der Formel (i) ist, worin R₄ und R₅ gemeinsam Methylendioxy bilden und R₃ (C₁-C₄)Alkyl ist.
6. Verbindung nach Anspruch 1, worin R₁ Wasserstoff, R₂ eine Gruppe der Formel (ii) ist, worin n 0 oder 1 ist und Het Furyl oder Pyridyl und R₃ (C₁-C₄)Alkyl ist.
7. Verbindung nach Anspruch 1, worin R₁ Wasserstoff, R₂ (C₁-C₄)Alkyl und R₃ Thienyl ist.
8. Pharmazeutische Zusammensetzung, die als aktiven Bestandteil eine Imidverbindung der Formel (I) oder ein pharmazeutisch verträgliches Salz davon nach irgendeinem der Ansprüche 1 bis 7 und einen pharmazeutisch verträglichen Träger umfaßt.
9. Pharmazeutische Zusammensetzung nach Anspruch 8, die ein Mittel für die Inhibierung der Produktion von Interleukin1β und der Produktion des Tumornekrosefaktors α ist.
10. Pharmazeutische Zusammensetzung nach Anspruch 8 oder 9, die ein therapeutisches Mittel gegen chronischen Rheumatismus, Sepsis, Colitis ulcerosa oder Morbus Crohn ist.
11. Pharmazeutische Zusammensetzung nach Anspruch 8 oder 9, die ein therapeutisches Mittel gegen Osteoarthritis, Behcet-Krankheit, systemischer Lupus erythematosus, Scleroderma, multiple Sklerose, Kawasaki-Syndrom, Guillain-Barre Syndrom, Abstoßung bei Organtransplantation, Nephritis, Hepatitis, Pankreatitis, Periarthritis nodosa, Cephalomeningitis, Meningitis, Periodontitis, Verbrennungen, Keloid, hypertrophe Narbe, Hornhautgeschwür, Psoriasis, Urtikaria, atopische Dermatitis, Pollenallergie, Asthma, Bronchitis, Hyperventilation bei Erwachsenen, Malaria, Hemikranie, Anorexia, Creutzfeldt-Jakob-Erkrankung, Osteoporose, Type II-Diabetes mellitus (NIDDM), Gicht, Atherosklerose, Dialyse-Hypotension, Cachexia durch Krebs oder infektiöse Erkrankungen oder erworbenes Immundefizit-Syndrom (AIDS).

Revendications


1. Un composé de type imide ayant la formule (I)




dans laquelle,

R₁ est de l'hydrogène, de l'halogène, du trifluorométhyle ou du cyano;

R₂ est de l'hydrogène, un alkyle en C₁ à C₄, un di-alkyl-(en C₁ à C₄)amino-alkyl (en C₁ à C₄), un groupe de la formule (i)




dans laquelle n est un nombre entier de 0 à 3, R₄ et R₅ représentent chacun indépendamment de l'hydrogène, de l'halogène, un alkyle en C₁ à C₄ ou un alcoxy en C₁ à C₄, ou bien R₄ et R₅ peuvent représenter conjointement un méthylènedioxy ou un groupe de la formule (ii)




dans laquelle n est un nombre entier de 0 à 3 et Het représente un groupe hétérocyclique à 5 ou 6 éléments, ayant de l'azote ou de l'oxygène comme hétéroatome ;

R₃ est un alkyle en C₁ à C₄, un alcoxy (en C₁ à C₄)-alkyle (en C₁ à C₄), un groupe de la formule (iii)



dans laquelle n est un nombre entier de 0 à 3, et R₆ est de l'hydrogène ou de l'halogène ou bien un groupe hétérocyclique à 5 ou 6 éléments, ayant de l'azote, de l'oxygène ou du soufre comme atome hétéro ; ou R₂ et R₃ conjointement avec un atome d'azote auquel R₂ est fixé et un groupe carbonyle auquel R₃ est fixé peut former un groupe hétérocyclique de la formule (iv)



dans laquelle m est un nombre entier de 1 à 4, Z est -CH₂-, -NH- ou -O-, et R₇ est de l'hydrogène, un alkyle en C₁ à C₄, un alcoxycarbonyle en C₁ à C₄, ou un phénylpropioyle, ou bien un sel pharmaceutiquement acceptable de celui-ci.

2. Le composé de la revendication 1, dans lequel R₁ est de l'hydrogène, de l'halogène, du trifluorométhyle ou du cyano et R₂ et R₃, conjointement avec un atome d'azote auquel R₂ est fixé et un groupe carbonyle auquel R₃ est fixé, forment un groupe hétérocyclique de la formule (iv) dans laquelle m est 1 ou 2, Z est -CH₂- ou -NH- et R₇ est de l'hydrogène, un alcoxycarbonyle en C₁ à C₄ ou un phénylpropioyle.
3. Le composé de la revendication 1, dans lequel R₁ est de l'hydrogène, R₂ est de l'hydrogène, un alkyle en C₁ à C₄ ou un di-alkyl (en C₁ à C₄)amino-alkyle (en C₁ à C₄), et R₃ est un alkyle en C₁ à C₄ ou un alcoxy (en C₁ à C₄) alkyle (en C₁ à C₄).
4. Le composé de la revendication 1, dans lequel R₁ est de l'hydrogène, R₂ est un groupe de formule (i) dans laquelle n est 0, 1 ou 2, R₄ et R₅ représentent chacun indépendamment de l'hydrogène, un halogène, un alkyle en C₁ à C₄, un alcoxy en C₁ à C₄, et R₃ est un groupe de la formule (iii) dans laquelle n est 0, 1 ou 2, R₆ est de l'hydrogène ou de l'halogène.
5. Le composé de la revendication 1, dans lequel R₁ est de l'hydrogène, R₂ est un groupe de la formule (i) dans laquelle R₄ et R₅ représentent conjointement un méthylènedioxy, et R₃ est un alkyle en C₁ à C₄.
6. Le composé de la revendication 1, dans lequel R₁ est de l'hydrogène, R₂ est un groupe de formule (ii) dans laquelle n est 0 ou 1 et Het représente du furyle ou du pyridyle et R₃ est un alkyle en C₁ à C₄.
7. Le composé de la revendication 1, dans lequel R₁ est de l'hydrogène, R₂ est un alkyle en C₁ à C₄ et R₃ est du thiényle.

8. Une composition pharmaceutique qui comporte, comme ingrédient actif, un composé de type imide de la formule (I) ou son sel pharmaceutiquement acceptable tel que revendiqué dans l'une quelconque des revendications 1 à 7, et un support pharmaceutiquement acceptable.
- 5 9. La composition pharmaceutique de revendication 8, celle-ci étant un agent pour inhiber la production d'interleukine-1 β et la production du facteur de nécrose tumorale α .
10. La composition pharmaceutique de la revendication 8 ou 9, celle-ci étant un agent thérapeutique pour le rhumatisme chronique, la septicémie, la colite ulcéreuse ou la maladie de Crohn.
- 10 11. La composition pharmaceutique de la revendication 8 ou 9, celle-ci étant un agent thérapeutique pour l'ostéoartrite, la maladie de Behcet, le lupus érythémateux systémique, la sclérodermie, la sclérose multiple, la maladie de Kawasaki, le syndrome de Guillain-Barre, les rejets de transplantation d'organes, la néphrite, l'hépatite, la pancréatite, la périartérite noneuse, la céphaloméningite, la méningite, la périodontite, les brûlures, la chéloïde, les cicatrices hypertrophiées, l'ulcération de la cornée, le psoriasis, l'urticaire, la dermatite atopique, l'allergie au pollen, 15 l'asthme, la bronchite, l'hyperventilation chez les adultes, la malaria, la migraine, l'anorexie, la maladie de Creutzfeldt-Jakob, l'ostéoporose, la glycosurie du diabète du type II (NIDDM), la goutte, l'athérosclérose, l'hypotension de dialyse, la cachexie par cancer ou maladie infectieuse, ou bien le syndrome immunodéficient acquis (SIDA).

20

25

30

35

40

45

50

55